Original Article

You have full text access to this OnlineOpen article

Treatment of children with Langerhans cell histiocytosis with 2-chlorodeoxyadenosine

  1. Carlos Rodriguez-Galindo1,2,*,
  2. Patrick Kelly1,2,
  3. Michael Jeng1,2,
  4. Gerald G. Presbury2,
  5. Martha Rieman1,
  6. Winfred Wang1,2

Article first published online: 20 FEB 2002

DOI: 10.1002/ajh.10053

Issue

American Journal of Hematology

American Journal of Hematology

Volume 69, Issue 3, pages 179–184, March 2002

Additional Information

How to Cite

Rodriguez-Galindo, C., Kelly, P., Jeng, M., Presbury, G. G., Rieman, M. and Wang, W. (2002), Treatment of children with Langerhans cell histiocytosis with 2-chlorodeoxyadenosine. Am. J. Hematol., 69: 179–184. doi: 10.1002/ajh.10053

Author Information

  1. 1

    Department of Hematology–Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee

  2. 2

    Department of Pediatrics, University of Tennessee School of Medicine, Memphis, Tennessee

*Department of Hematology–Oncology, St. Jude Children's Research Hospital, 332 N. Lauderdale, Memphis, TN 38105

Publication History

  1. Issue published online: 20 FEB 2002
  2. Article first published online: 20 FEB 2002
  3. Manuscript Accepted: 15 OCT 2001
  4. Manuscript Received: 12 APR 2001

Funded by

  • American Lebanese Syrian Associated Charities (ALSAC).

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

Get PDF (121K)

REFERENCES

  • 1
    Arico M, Egeler RM. Clinical aspects of Langerhans cell histiocytosis. Hematol Oncol Clin North Am 1998; 12: 247–258.
  • 2
    Yu RC, Chu C, Buluwela L, Chu AC. Clonal proliferation of Langerhans cells in Langerhans cell histiocytosis. Lancet 1994; 343: 767–768.
  • 3
    Willman CL, Busque L, Griffith BB, Favora BE, McClain KL, Duncan MH, Gilliland DG. Langerhans' cell histiocytosis (histiocytosis X)—a clonal proliferative disease. N Engl J Med 1994; 331: 154–160.
  • 4
    Broadbent V, Pritchard J, Davies EG. Spontaneous remission of multisystem histiocytosis X. Lancet 1984; 1: 253–254.
  • 5
    Mahmoud HH, Wang WC, Murphy SB. Cyclosporine therapy for advanced Langerhans cell histiocytosis. Blood 1991; 77: 721–725.
  • 6
    Ceci A, de Terlizzi M, Colella R, Loiacono G, Balducci D, Surico G, Castello M, Testi AM, De Bernardi B, Indolfi P, Macchia P, Madon E, Mancini A, Rosati D. Langerhans cell histiocytosis in childhood: results from the Italian Cooperative. Med Pediatr Oncol 1993; 21: 259–264.
    Direct Link:
  • 7
    Gadner H, Heiger A, Grois N, Gatterer-Menz I, Ladisch S. Treatment strategy for disseminated Langerhans cell histiocytosis. Med Pediatr Oncol 1994; 23: 72–80.
    Direct Link:
  • 8
    Broadbent V, Gadner H. Current therapy for Langerhans cell histiocytosis. Hematol Oncol Clin North Am 1998; 12: 327–338.
  • 9
    Womer RB, Anunciato KR, Chehrenama M. Oral methotrexate and alternate-day prednisone for low-risk Langerhans cell histiocytosis. Med Pediatr Oncol 1995; 25: 70–73.
    Direct Link:
  • 10
    Ladisch S, Gadner H, Arico M, Broadbent V, Grois N, Jacobson A, Komp DM, Nicholson HS. LCH-I: a randomized trial of etoposide vs. vinblastine in disseminated Langerhans cell histiocytosis. Med Pediatr Oncol 1994; 23: 107–110.
    Direct Link:
  • 11
    Arico M, Colella R, Conter V, Indolfi P, Pession A, Santoro N, Burgio GR. Cyclosporine therapy for refractory Langerhans cell histiocytosis. Med Pediatr Oncol 1995; 25: 12–16.
    Direct Link:
  • 12
    Greinix HT, Storb R, Sanders JE, Petersen FB. Marrow transplantation for treatment of multisystem progressive Langerhans cell histiocytosis. Bone Marrow Transplant 1992; 10: 39–44.
  • 13
    Saven A, Foon KA, Piro LD. 2-Chlorodeoxyadenosine-induced complete remissions in Langerhans-cell histiocytosis. Ann Intern Med 1994; 121: 430–432.
  • 14
    Saven A, Burian C. Cladribine activity in adult Langerhans-cell histiocytosis. Blood 1999; 93: 4125–4130.
  • 15
    Stine KC, Saylors RL, Williams LL, Becton DL. 2-Chlorodeoxyadenosine (2-CDA) for the treatment of refractory or recurrent Langerhans cell histiocytosis (LCH) in pediatric patients. Med Pediatr Oncol 1997; 29: 288–292.
    Direct Link:
  • 16
    Weitzman S, Wayne AS, Arceci R, Lipton JM, Whitlock JA, De Rossi G. Nucleoside analogues in the therapy of Langerhans cell histiocytosis: a survey of members of the Histiocyte Society and review of the literature. Med Pediatr Oncol 1999; 33: 476–481.
    Direct Link:
  • 17
    Carson DA, Wasson DB, Kaye J, Ullman B, Martin DW, Robins RK, Montgomery JA. Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant lymphoblasts in vitro and toward murine L1210 leukemia in vivo. Proc Natl Acad Sci USA 1980; 77: 6865–6869.
  • 18
    Guchelaar H-J, Richel DJ, Schaafsma MR. Clinical and toxicological aspects of the antineoplastic drug cladribine: a review. Ann Hematol 1994; 69: 223–230.
  • 19
    Avery TL, Rehg JE, Lumm WC, Harwood FC, Santana VM, Blakley RL. Biochemical pharmacology of 2-chlorodeoxyadenosine in malignant human hematopoietic cell lines and therapeutic effects of 2-bromodeoxyadenosine in drug combinations in mice. Cancer Res 1989; 49: 4972–4978.
  • 20
    Robertson LE, Chubb S, Meyn RE, Story M, Ford R, Hittelman WN, Plunkett W. Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2′-deoxyadenosine and 9-β-D-arabinosyl-2-fluoroadenine. Blood 1993; 81: 143–150.
  • 21
    Saven A. The Scripps Clinic experience with cladribine (2-CdA) in the treatment of chronic lymphocytic leukemia. Semin Hematol 1996; 33 (Suppl 1): 28–33.
  • 22
    Hoffman MA. Cladribine for the treatment of indolent non-Hodgkin's lymphomas. Semin Hematol 1996; 33 (Suppl 1): 40–44.
  • 23
    Estey EH, Kurzrock R, Kantarjian HM, O'Brien SM, McCredie KB, Beran M, Koller C, Keating MJ, Hirsch-Ginsberg C, Huh YO, Stass S, Freireich EJ. Treatment of hairy-cell leukemia with 2-chlorodeoxyadenosine (2-CdA). Blood 1992; 79: 882–887.
  • 24
    Piro LD, Carrera CJ, Carson DA, Beutler E. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med 1990; 322: 1117–1121.
  • 25
    Santana VM, Mirro J, Kearns C, Schell M, Crom W, Blakley RL. 2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia. J Clin Oncol 1992; 10: 364–370.
  • 26
    Carson DA, Wasson DB, Taetle R, Yu A. Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood 1983; 62: 737–743.
  • 27
    Beutler E. New chemotherapeutic agent: 2-chlorodeoxyadenosine. Semin Hematol 1994; 31: 40–45.
  • 28
    Santana VM, Mirro J, Harwood FC, Cherrie J, Schell M, Kalwinsky D, Blakley RL. A phase I clinical trial of 2-chlorodeoxyadenosine in pediatric patients with acute leukemia. J Clin Oncol 1991; 9: 416–422.
  • 29
    Liliemark J, Juliusson G. Cellular pharmacokinetics of 2-chloro-2′-deoxyadenosine nucleotides: comparison of intermittent and continuous intravenous infusion and subcutaneous and oral administration in leukemia patients. Clin Cancer Res 1995; 1: 385–390.
  • 30
    Larson RA, Mick R, Spielberger RT, O'Brien SM, Ratain MJ. Dose-escalation trial of cladribine using five daily intravenous infusions in patients with advanced hematologic malignancies. J Clin Oncol 1996; 14: 188–195.
  • 31
    Spasokoukotskaja T, Arnér ESJ, Brosjö O, Juliusson G, Juliusson G, Liliemark J, Eriksson S. Expression of deoxycytidine kinase and phosphorylation of 2-chlorodeoxyadenosine in human and tumour cells and tissues. Eur J Cancer 1995; 31A: 202–208.
  • 32
    Carrera CJ, Terai C, Lotz M, Curd JG, Piro LD, Beutler E, Carson DA. Potent toxicity of 2-chlorodeoxyadenosine toward human monocytes in vitro and in vivo. J Clin Invest 1990; 86: 1480–1488.
  • 33
    Dimopoulos MA, Theodorakis M, Kostis E, Papadimitris C, Moulopoulos LA, Anastasiou-Nana M. Treatment of Langerhans cell histiocytosis with 2-chlorodeoxyadenosine. Leuk Lymphoma 1997; 25: 187–189.
  • 34
    McCowage GB, Frush DP, Kurtzberg J. Successful treatment of two children with Langerhans' cell histiocytosis with 2′-deoxycoformycin. J Pediatr Hematol Oncol 1996; 18: 154–158.
  • 35
    Lombardi A, El Hachem MC, Rana I, De Rossi G. 2′-Deoxycoformycin as treatment in refractory Langerhans cell histiocytosis (letter). J Pediatr 1997; 130:330.
  • 36
    Emile JF, Fraitag S, Leborgne M, de Prost Y, Brousse N. Langerhans' cell histiocytosis cells are activated Langerhans' cells. J Pathol 1994; 174: 71–76.
    Direct Link:
  • 37
    Yu RC, Morris JF, Pritchard J, Chu TC. Defective alloantigen-presenting capacity of Langerhans cell histiocytosis cells. Arch Dis Child 1992; 67: 1370–1372.
  • 38
    Kannourakis G, Abbas A. The role of cytokines in the pathogenesis of Langerhans cell histiocytosis. Br J Cancer 1994; 70 (Suppl 23): S37–S40.
  • 39
    Schultz C, Klouche M, Friedrichsdorf S, Richter N, Kroehnert B, Bucsky P. Langerhans cell histiocytosis in children: does soluble Interleukin-2-receptor correlate with both disease extent and activity? Med Pediatr Oncol 1998; 31: 61–65.
    Direct Link:
  • 40
    Juliusson G, Lenkei R, Liliemark J. Flow cytometry of blood and bone marrow cells from patients with hairy cell leukemia: phenotype of hairy cells and lymphocyte subsets after treatment with 2-chlorodeoxyadenosine. Blood 1994; 83: 3672–3681.
  • 41
    Seymour JF, Kurzrock R, Freireich EJ, Estey EH. 2-Chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy-cell leukemia. Blood 1994; 83: 2906–2911.
  • 42
    Wijermans PW, Gerrits WBJ, Haak HL. Severe immunodeficiency in patients treated with fludarabine monophosphate. Eur J Haematol 1993; 50: 292–296.
    Direct Link:
  • 43
    Van Den Este E, Delannoy A, Vandercam B, Bosly A, Ferrant A, Mineur P, Montfort L, Martiat P, Straetmans N, Filleul P, Michaux JL. Infectious complications after 2-chlorodeoxyadenosine therapy. Eur J Haematol 1996; 56: 235–240.
  • 44
    Beutler E, Sipe J, Romine JS, McMillan R, Zyroff J, Koziol JA. Treatment of multiple sclerosis and other autoimmune diseases with cladribine. Semin Hematol 1996; 33 (Suppl 1): 45–52.
  • 45
    Willis B, Ablin A, Weinberg V, Zoger S, Wara WM, Matthay KK. Disease course and late sequelae of Langerhans' cell histiocytosis: 25-year experience at the University of California, San Francisco. J Clin Oncol 1996; 14: 2073–2082.
Get PDF (121K)